stockportfolio.pro
Stocks / GILD vs MRK
GILD vs MRK
Gilead Sciences, Inc. and Merck & Co., Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
MRK is the larger company ($285.1B vs $155.8B). On the fundamentals, MRK grows revenue faster (9.4% vs 3.6%); GILD earns a higher net margin (28.9% vs 28.1%); GILD has the stronger return on equity (37.5% vs 34.7%). Full numbers below — the stronger figure on each row is in green.
| Gilead Sciences, Inc. (GILD) | Merck & Co., Inc. (MRK) | |
|---|---|---|
| Market cap | $155.8B | $285.1B |
| Revenue (latest FY) | $29.44B | $65.01B |
| Net income (latest FY) | $8.51B | $18.25B |
| Revenue growth (5y CAGR) | 3.6% | 9.4% |
| Net margin | 28.9% | 28.1% |
| Return on equity | 37.5% | 34.7% |
| P/E ratio | 17.1 | 32.5 |
| Dividend yield | 2.6% | 2.9% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare with another company:
See the full GILD vs MRK breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open GILD's full financials → Open MRK's full financials →More comparisons
Frequently asked questions
Which is bigger, GILD or MRK?
Merck & Co., Inc. is larger by market capitalization — $285.1B versus $155.8B.
Which grows faster, GILD or MRK?
Over the last five fiscal years, Merck & Co., Inc. grew revenue faster — 9.4%/yr versus 3.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.